These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 28839086)

  • 21. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.
    López-Cortés LF; Ruiz-Valderas R; Viciana P; Alarcón-González A; Gómez-Mateos J; León-Jimenez E; Sarasanacenta M; López-Pua Y; Pachón J
    Clin Pharmacokinet; 2002; 41(9):681-90. PubMed ID: 12126459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug interaction between rifampin and nortriptyline: a case report.
    Bebchuk JM; Stewart DE
    Int J Psychiatry Med; 1991; 21(2):183-7. PubMed ID: 1894457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients.
    Ruslami R; Nijland HM; Alisjahbana B; Parwati I; van Crevel R; Aarnoutse RE
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2546-51. PubMed ID: 17452486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
    Alfarisi O; Alghamdi WA; Al-Shaer MH; Dooley KE; Peloquin CA
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1027-1036. PubMed ID: 28803492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.
    Droste JA; Verweij-van Wissen CP; Kearney BP; Buffels R; Vanhorssen PJ; Hekster YA; Burger DM
    Antimicrob Agents Chemother; 2005 Feb; 49(2):680-4. PubMed ID: 15673751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Side Effects of Rifampin versus Isoniazid in Children.
    Diallo T; Adjobimey M; Ruslami R; Trajman A; Sow O; Obeng Baah J; Marks GB; Long R; Elwood K; Zielinski D; Gninafon M; Wulandari DA; Apriani L; Valiquette C; Fregonese F; Hornby K; Li PZ; Hill PC; Schwartzman K; Benedetti A; Menzies D
    N Engl J Med; 2018 Aug; 379(5):454-463. PubMed ID: 30067928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
    Monaldi Arch Chest Dis; 1994 Sep; 49(4):327-45. PubMed ID: 8000420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):707-12. PubMed ID: 1901200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
    Dorman SE; Savic RM; Goldberg S; Stout JE; Schluger N; Muzanyi G; Johnson JL; Nahid P; Hecker EJ; Heilig CM; Bozeman L; Feng PJ; Moro RN; MacKenzie W; Dooley KE; Nuermberger EL; Vernon A; Weiner M;
    Am J Respir Crit Care Med; 2015 Feb; 191(3):333-43. PubMed ID: 25489785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mathematical modeling of pulmonary tuberculosis therapy: Insights from a prototype model with rifampin.
    Goutelle S; Bourguignon L; Jelliffe RW; Conte JE; Maire P
    J Theor Biol; 2011 Aug; 282(1):80-92. PubMed ID: 21605569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low isoniazid and rifampicin concentrations in TB/HIV co-infected patients in Uganda.
    Wiltshire CS; Lamorde M; Scherrer A; Musaazi J; Corti N; Allan B; Nakijoba R; Nalwanga D; Henning L; Von Braun A; Okware S; Castelnuovo B; Kambugu A; Fehr J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19585. PubMed ID: 25394091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues.
    Skevaki CL; Kafetzis DA
    Paediatr Drugs; 2005; 7(4):219-34. PubMed ID: 16117559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for rifampin mono-resistant tuberculosis.
    Ridzon R; Whitney CG; McKenna MT; Taylor JP; Ashkar SH; Nitta AT; Harvey SM; Valway S; Woodley C; Cooksey R; Onorato IM
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1881-4. PubMed ID: 9620922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.
    Acosta EP; Kendall MA; Gerber JG; Alston-Smith B; Koletar SL; Zolopa AR; Agarwala S; Child M; Bertz R; Hosey L; Haas DW
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3104-10. PubMed ID: 17576825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model.
    Lyons MA; Lenaerts AJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):375-89. PubMed ID: 26026426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erratum for Lakota et al., "Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data".
    Lakota EA; Ong V; Flanagan S; Rubino CM
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30917976
    [No Abstract]   [Full Text] [Related]  

  • 37. Erratum for Alsultan et al., "Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis".
    Alsultan A; Furin JJ; Du Bois J; van Brakel E; Chheng P; Venter A; Thiel B; Debanne SA; Boom WH; Diacon AH; Johnson JL; Peloquin CA
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29269434
    [No Abstract]   [Full Text] [Related]  

  • 38. Erratum for Dai et al., "Autoantibody-Mediated Erythrophagocytosis Increases Tuberculosis Susceptibility in HIV Patients".
    Dai Y; Cai Y; Wang X; Zhu J; Liu X; Liu H; Li L; Zhang Y; Liu S; Wen Z; Feng CG; Chen X; Tang X
    mBio; 2020 Mar; 11(2):. PubMed ID: 32234816
    [No Abstract]   [Full Text] [Related]  

  • 39. Erratum for Alexander et al., Emerging Tuberculosis Pathogen Hijacks Social Communication Behavior in the Group-Living Banded Mongoose (Mungos mungo).
    Alexander KA; Sanderson CE; Larsen MH; Robbe-Austerman S; Williams MC; Palmer MV
    mBio; 2016 Jun; 7(3):. PubMed ID: 27329748
    [No Abstract]   [Full Text] [Related]  

  • 40. Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis".
    Peloquin CA; Velásquez GE; Lecca L; Calderón RI; Coit J; Milstein M; Osso E; Jimenez J; Tintaya K; Garavito ES; Vasquez DV; Mitnick CD; Davies G
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28839086
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.